论文部分内容阅读
目的探讨抗栓治疗患者肉眼血尿的成因、治疗及预防。方法回顾性分析865例抗栓治疗后并发肉眼血尿患者的临床资料。结果前列腺增生相关血尿431例(49.9%),导尿相关血尿175例(20.2%),泌尿系感染130例(15.0%),泌尿系结石57例(6.6%),前列腺癌13例(1.5%),移行上皮肿瘤9例(1.0%),肾肿瘤3例(0.3%),内科血尿4例(0.5%),不明原因血尿43例(5.0%)。经保守治疗,绝大多数患者肉眼血尿消失,时间为0.5～18d。1例经尿道电凝止血,3例行髂内动脉栓塞,2例行膀胱切开清除血块。结论抗栓药物的使用与血尿关系密切。前列腺增生相关血尿和导尿相关血尿最常见。恰当选择保守或手术治疗可以有效控制血尿。全面检查有助于发现抗栓治疗后并发血尿患者的重要泌尿系统疾病。预防措施可以减少术后发生血尿的风险。
Objective To investigate the causes, treatment and prevention of gross hematuria in patients treated with antithrombotic therapy. Methods The clinical data of 865 patients with gross hematuria after antithrombotic therapy were retrospectively analyzed. Results 431 cases of benign prostatic hyperplasia (49.9%), catheter-related hematuria (20.2%), 130 cases of urinary tract infection (15.0%), 57 cases of urinary calculi (6.6%), 13 cases of prostate cancer (1.5% ), 9 cases of transitional epithelial tumor (1.0%), 3 cases of renal tumor (0.3%), 4 cases of hematuria (0.5%) and 43 cases of unknown hematuria (5.0%). After conservative treatment, the vast majority of patients with gross hematuria disappear, the time is 0.5 ~ 18d. One case of transurethral electrocoagulation to stop bleeding, three cases of internal iliac artery embolization, 2 cases of bladder incision to remove the clot. Conclusion The use of antithrombotic drugs is closely related to hematuria. Prostatic hyperplasia-related hematuria and catheterization-related hematuria are the most common. Proper choice of conservative or surgical treatment can effectively control hematuria. A thorough examination can help identify important urologic disorders in patients with hematuria after antithrombotic therapy. Precautions can reduce the risk of postoperative hematuria.